Valneva SE ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY EPS (est.)
-$1.44next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| 9M 2026 Financial Results | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Product Sales Revenue Annually163.3MTarget: €135 million to €150 million
Total Revenues Annually169.6MTarget: €145 million to €160 million
Operating Expense Reduction AnnuallyTarget: 25% to 35% reduction compared to 2025 levels
Watch Items
- Pfizer Regulatory Submissions for Lyme Disease Vaccine Candidate PF-07307405 (LB6V)Trigger: Submission of marketing applications to FDA and EMAAction: Monitor partner Pfizer's timeline and regulatory feedback following the Phase 3 VALOR trial results.
- IXCHIQ Global Commercial Rollout and Post-Marketing ActivitiesTrigger: Execution of Phase 4 clinical trials and real-world safety monitoringAction: Track safety data and regulatory recommendations in Europe, Canada, the UK, and Brazil following the voluntary US withdrawal.
- Restructuring Plan and Workforce ReductionTrigger: 10% to 15% global workforce reductionAction: Assess the impact of cost-saving measures on operational efficiency and R&D execution.
Research as of 19 Jun 2026